Substitute form 1449A/PTO	OF	Complete if Known	
	17 - 40g	Application Number	10/008,062
INFORMATION DISCLOSURE	/0	Filing Date	10/19/2001
STATEMENT BY APPLICANT	_ 0 10 1	First Named Inventor	David Rizzieri
STATEMENT BY ATTEMAT		Group Art Unit	1642 (643
(use as many sheets as necessary)	1 20	Examiner Name	Alana M. Harris
Sheet 1 of	1 78	Attorney Docket Number	5405-252
	A TRADE		

			U.S. PATENTS A	ND PATENT PUBLICATIONS		
Examiner Cite No.	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
		Number	Kind Code (if known)	Document	MM-DD-YYYY	
		US-				
		US-				
		US-				
	i i	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			•	
		US-				
		US-				
		US-				
		US-				

				FOREIGN PA	ATENT DOCUMENTS		
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited  Document	Date of Publication of	Translation
		Office	Number	Kind Code (if known)	Document	Cited Document MM-DD-YYYY	
ann	1	wo	92/04464	A2	The Wistar Institute	03/19/1992	
		+					
	+-	<del> </del>			-		

	OTHER NON PATENT LITERATURE DOCUMENTS	
Cite No.	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Т
2	Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005	
3	Kaminski et al., "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96(4):1259-1266 (2000)	
		<del> </del> -
		+
	No. 2	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published  Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005  Kaminski et al., "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan

Examiner Signature	and Obicis	Date Considered	03/	07/2006	